Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $6.3 million.

  • Nurix Therapeutics' Change in Accured Expenses rose 4.94% to $6.3 million in Q3 2025 from the same period last year, while for Aug 2025 it was $15.3 million, marking a year-over-year increase of 160.64%. This contributed to the annual value of $11.8 million for FY2024, which is 278.35% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Change in Accured Expenses of $6.3 million as of Q3 2025, which was up 190.44% from -$7.0 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Change in Accured Expenses ranged from a high of $9.0 million in Q4 2024 and a low of -$7.0 million during Q2 2025.
  • For the 3-year period, Nurix Therapeutics' Change in Accured Expenses averaged around $1.9 million, with its median value being $3.6 million (2024).
  • As far as peak fluctuations go, Nurix Therapeutics' Change in Accured Expenses skyrocketed by 314.68% in 2022, and later crashed by 402.88% in 2024.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Change in Accured Expenses stood at $3.4 million in 2021, then declined by 2.51% to $3.3 million in 2022, then decreased by 6.71% to $3.1 million in 2023, then surged by 193.46% to $9.0 million in 2024, then increased by 4.94% to $6.3 million in 2025.
  • Its Change in Accured Expenses stands at $6.3 million for Q3 2025, versus -$7.0 million for Q2 2025 and $6.9 million for Q1 2025.